Oligopeptide-1 / EGF Dosing & Reconstitution Guide

Oligopeptide-1 can be administered via topical or intralesional routes, with distinct dosing guidelines for each application. For topical use, research indicates a frequency of 1 to 2 applications daily, utilizing serums containing concentrations between 1 to 10 parts per million (ppm) of recombinant human EGF (rh-EGF). In contrast, intralesional administration, as exemplified by Heberprot-P, is typically conducted three times weekly, with a recommended dose of 75 micrograms per injection. These dosing regimens are drawn from various studies evaluating the efficacy of EGF in wound healing and cosmetic applications. However, it is critical to note that individual responses may vary, and the outlined dosing should be contextualized within specific research frameworks.

Oligopeptide-1 is generally well tolerated in both wound healing and cosmetic applications, with studies indicating minimal systemic absorption when applied topically at cosmetic concentrations. While the theoretical risk of EGF receptor activation exists—potentially promoting the growth of pre-existing malignancies—this concern is primarily associated with therapeutic doses used in wound healing rather than the trace concentrations typical in cosmetic formulations. Contraindications include the presence of active skin cancer or suspicious lesions in the treatment area for wound healing applications, as well as known hypersensitivity to EGF or its formulation components. Researchers must ensure that these safety considerations are thoroughly evaluated prior to conducting experiments involving Oligopeptide-1.